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Abstract
Interstitial lung disease (ILD) is the primary cause of death in patients with systemic sclerosis (SSc). It is thought that chronic
inflammation is a key component in SSc-ILD. Treatment, such as cyclophosphamide (CYC), targets this inflammation. We
hypothesized that treatment with CYC might be more effective in the inflammatory phase. Therefore, we analyzed whether the
extent of inflammation, as assessed by the proportion of ground glass compared to fibrosis, SSc disease duration, the extent of
ILD, or baseline diffusion capacity of the lungs (DLCO) < 60%, modifies the effect of intravenous CYC pulse therapy (750 mg/
m2) on pulmonary function (as measured by FVC, DLCO) in SSc-ILD patients, after 12, 24, and 36months. Consecutive patients
with SSc-ILD receiving CYC pulses between 2003 and 2015 were included. Pulmonary function tests were performed at 0, 6, 12,
24, and 36 months. There were 75 patients included. Forced vital capacity (FVC) (86% of predicted) and DLCO (42% of
predicted) were stable after 12, 24 and 36 months of follow-up (p > 0.05). Forty-four patients completed 12 cycles of CYC.
For the extent of ILD, proportion of ground glass compared to fibrosis, SSc disease duration, and baseline DLCO, there were no
differences (all p > 0.05) in the course of FVC and DLCO. Treatment with CYC followed by maintenance therapy stabilizes
pulmonary function in patients with SSc-ILD over a 3-year period. The extent of ILD, proportion of ground glass, SSc disease
duration, and baseline DLCO < 60% did not influence the effect of CYC on pulmonary function.
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Introduction
Systemic sclerosis (SSc) is a generalized auto-immune disease
characterized by inflammation, micro-vasculopathy, and
fibrosis, affecting skin and internal organs. The primary cause
of death in patients with SSc is interstitial lung disease (ILD)
[1]. The incidence of ILD in SSc varies from 25 to 90% de-
pending on the method used to identify ILD [2], with a 10-
year survival rate in SSc-ILD patients of 70% from onset of
SSc-ILD [3]. Although the pathogenesis of SSc-ILD has not
been elucidated, it is hypothesized that chronic inflammation
of the alveoli leads to progressive lung tissue damage and
increasing fibrosis [4–8].
According to EULAR recommendations, cyclophospha-
mide (CYC) is the first choice of therapy for treating SSc-
ILD [9]. Cyclophosphamide acts as a cytotoxic immunosup-
pressive agent through modulation of lymphocyte function
that leads to depression of the inflammatory response and less
fibrosis [10, 11]. Several uncontrolled studies showed a posi-
tive effect on pulmonary function in patients receiving cyclo-
phosphamide [12–19]. Based on these studies, two double-
blind placebo-controlled randomized controlled trials were
subsequently carried out [20, 21]. The first, the scleroderma
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lung study (SLSI), investigated oral CYC and showed a small
positive effect on pulmonary function and quality of life after
12 months compared to placebo, which did not sustain after
24 months. The second, the UK lung study, showed a trend
towards improvement of forced vital capacity (FVC) after six
monthly intravenous (IV) CYC pulses during 12months com-
pared to placebo. A third study (SLSII) compared CYC to
mycophenolate mofetil (MMF) in a randomized controlled
setting. Both CYC and MMF were proven to be equally ef-
fective in SSc-ILD after 24 months. These results show that
CYC can have an effect, albeit small, on pulmonary function
in SSc-ILD and quality of life.
The small effect of these studies might be caused by differ-
ences in dosage, treatment duration, and administration route
as well as a longer SSc disease duration. In the Radboud
University Medical Center, patients with SSc-ILD are treated
with monthly CYC pulses according to a protocol in which
patients are givenmonthly ivCYC (750mg/m2) for 12months
as soon as the ILD is diagnosed. We hypothesized that the
effects of CYC in our cohort of SSc-ILD patients would be
equal to or larger than in the aforementioned trials, because of
this upfront, high-dose treatment protocol. We also hypothe-
sized that, based on what is known about the mechanism of
action of CYC in SSc-ILD [22], CYCmay have a larger effect
in an Bactive^ inflammatory phase of SSc-ILD than in a later
fibrotic phase.
Therefore, in this study, we analyzed whether the extent of
inflammation, as assessed by the proportion of ground glass
compared to fibrosis, SSc disease duration, the extent of ILD,
or baseline diffusion capacity of the lungs (DLCO) < 60%,
modifies the effect of intravenous CYC pulse therapy
(750 mg/m2) on pulmonary function (as measured by FVC,
DLCO) in SSc-ILD patients, after 12, 24, and 36 months.
Methods
Design
This retrospective study was designed as an observational,
long-term cohort including prospective data collection and
intention-to-treat analysis. Since 2003, intravenous, monthly
CYC pulse therapy is the first of choice therapy for SSc-ILD
and/or rapid progressive diffuse SSc at our Department of
Rheumatology of the Radboudumc. All patients since then
diagnosed with SSc-ILD who started treatment with monthly
iv CYC pulses (dose 750 mg/m2) were analyzed in this study.
Pulmonary function tests (FVC and DLCO) obtained during
scheduled follow-up were used to analyze the treatment effect
of CYC at 12, 24, and 36 months after start of CYC pulses.
Variables that were chosen to reflect the concept of an Bactive^
inflammatory phase of SSc-ILD included the percentage of
ground glass, SSc disease duration, extent of ILD by Goh’s
classification criteria, and baseline DLCO. These variables
were used as inflammatory proxies to analyze the effect on
pulmonary function test results over time. Occurrence of ad-
verse events (AE) and survival were also analyzed.
Due to the observational nature of this cohort, no ethical
review was needed according to Dutch law and regulations.
Patients
All patients with SSc-ILD as indicated by high-resolution
computed tomography (HRCT) who started intravenous
CYC pulse therapy from 2003 in the Radboudumc were in-
cluded in this study. Patients who received cyclophosphamide
for skin involvement were not analyzed in this study. The
dosage of CYC was 750 mg/m2. Presence of SSc-ILD was
defined as presence of ground glass opacity (GGO) or
honeycombing or pulmonary fibrosis on HRCT. Patients were
followed from the start of CYC treatment up to 3 years. Most
patients in our center received mycophenolate mofetil follow-
ing CYC infusions, during at least 3 years. Before 2013, pa-
tients received MMF with an increasing rate; other patients
received azathioprine or no follow-up treatment; from 2013
onwards, follow-up treatment with MMF is the standard.
Assessments
Baseline demographic and clinical data and results from pul-
monary function tests (PFTs) and HRCT were collected.
Occurrence of the first non-Raynaud (NR) symptom was
appointed as disease onset of SSc. Pulmonary function testing
was performed at 6, 12, 24, and 36 months after the start of
CYC pulses. Spirometry (FVC) and carbon monoxide DLCO
were performed according the ATS/ERS guidelines [23].
Predicted normal values were derived from the European
Community for Steel and Coal [24].
The presence and extent of GGO and fibrosis on HRCT
was assessed according to the criteria by Goh for limited and
extensive ILD. HRCT images were scored at five levels: (1)
origin of great vessels, (2) main carina, (3) pulmonary venous
confluence, (4) halfway between the third and fifth sections,
(5) immediately above the right hemi-diaphragm. The total
extent of interstitial lung disease was estimated to the nearest
5 % in each of the five sections, with global extent of disease
on HRCT computed as the mean of the scores [25].
Two independent physicians were blinded for patient char-
acteristics including PFT results and blinded for purpose of the
study performed this assessment, respectively. Cases in which
there was disagreement were discussed in a consensus meet-
ing and consensus was reached in every case.
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Outcomes
The primary endpoint in this study was the FVC after
12 months since the first CYC infusion. Secondary outcomes
in pulmonary function were DLCO after 12 months, FVC and
DLCO after 24 and 36 months, and therapy response accord-
ing to the American Thoracic Society [26]. A good response
to therapy was defined as an increase in FVC of > 10% or an
increase in DLCO > 15% compared to baseline (treatment
start) [5, 17, 19, 26, 27]. Stabilization was defined as a change
in FVC of < 10% and DLCO of < 15%, and a decrease of >
10% in FVC or > 15% in DLCO as worsened SSc-ILD [28].
Further, secondary outcomes were serious adverse events
(SAEs) and death related to ILD.
Effect modifiers
Effect modifiers of interest, reflecting inflammatory activity of
ILD by proxy, were the presence of more GGO than fibrosis,
SSc disease duration < 3 years, the extent of ILD according to
Goh, and DLCO < 60% at baseline. The method of Goh was
used to determine whether limited or extensive ILD was pres-
ent [25]. This staging system consists of a combination of
HRCT scan and PFT data and provides discriminatory prog-
nostic information on SSc-ILD [25]. In short, the disease ex-
tent on HRCT scan (more or less than 20% of the surface of
the lungs) is combinedwith FVC% predicted (higher or lower
than 70%) to stage the ILD as limited or extensive disease
[25].
Statistical analysis
All analyses of FVC and DLCO were conducted on all pa-
tients with SSc-ILD starting a first pulse with CYC. Missing
outcome data due to dropout were replaced by the last obser-
vation carried forward (LOCF), except in the case of death.
Per-protocol analysis was also done, including all patients
finishing a complete course of 12 pulses [29, 30].
The effect of the predefined variables, chosen to reflect the
concept of an Bactive^ inflammatory phase of SSc-ILD, on the
effect of CYC on pulmonary function was analyzed. Linear
regression analysis was performed with ΔFVC and with
ΔDLCO as the dependent variable. For these analyses, poten-
tial confounders were regarded as actual confounders if their
inclusion led to a change of > 10% of the regression coeffi-
cient of the group effect. Analyses were done for every time
point: the difference in FVC and DLCO between 0 vs.
12 months, 0 vs. 24 months, and 0 vs. 36 months. All four
probable effect modifiers were analyzed separately.
Further, it was explored whether there were baseline differ-
ences between responders and poor responders using
Student’s t test, Mann–Whitney U test, chi-square test, or
Fisher’s exact test, as appropriate. Occurrence of SAEs was
tabulated; survival was analyzed using a Kaplan-Meier plot. A
p value < 0.05 was deemed to notify statistical significance.
Analyses were done using SPSS version 22.0.
Results
A total of 91 SSc patients were treated with CYC pulses for
SSc-ILD; 16 patients were excluded due to the lack of a base-
line HRCT (n = 15) or PFT (n = 1). Baseline characteristics of
the 75 eligible patients are summarized in Table 1. Patients
with diffuse cutaneous SSc (dcSSc) were more often male
with a shorter disease duration. Fibrosis on HRCT was the
most prevalent abnormality at baseline and was found in
95% of the patients; GGO was found in 76% of the patients.
Both fibrosis and GGO were most often present in the lower
lung fields.
Course over time
PFT results after 12, 24, and 36 months are shown in Fig. 1.
Both FVC and DLCO showed a non-significant increase.
Table 2 displays the change in FVC and DLCO between base-
line and 12, 24, and 36 months, sequentially. Results are
shown for the raw data, data adjusted with LOCF and the
per-protocol analysis (PPA) of all patients who completed 12
cycles of CYC (n = 44). On average, forced vital capacity after
36 months was 1% higher than baseline (95% CI, − 5.5–
7.5%). Similarly, there was a non-significant increase of
1.6% (95% CI, − 2.5–5.7) in DLCO after 36 months com-
pared to baseline. Adjusting results for lost-to-follow-up and
per-protocol did not lead to significant changes.
Effect modifiers
To investigate whether the treatment effect was more pro-
nounced in the early inflammatory phase, we identified four
proxies for active, early inflammation: GGO, disease duration,
extent of ILD, and baseline DLCO (see BMethods^). In Table
3, BGGO > fibrosis^ indicates the difference between GGO >
fibrosis and GGO < fibrosis. This is similar for the analyses of
the variables Bdisease duration < 3 years,^ Blimited vs. exten-
sive ILD,^ and Bbaseline DLCO < 60%.^
None of these proxies for early, active inflammation were
associated with a higher treatment effect. For example, the
change in percentage of predicted FVC values between 0
and 12 months differed 0.2% between GGO > fibrosis and
GGO < fibrosis, which was a non-significant difference (p =
0.92). The other probable effect modifiers also showed no
significant differences in both FVC and DLCO at all follow-
up time points. In the per-protocol analysis in the 44 patients
who completed 12 cycles of CYC pulse therapy, similar re-
sults were seen (not shown).
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Responders
Out of the 75 patients who started treatment with CYC pulses,
14 patients (18.7%) fulfilled the good response criteria during
follow-up. A total of 41 patients (54.7%) stabilized and 20
patients (26.7%) worsened during follow-up.
There was a significant difference (p = 0.008) between the
different response groups in SSc disease duration: the good
responders had a median disease duration of 10 months (p25–
p75: 4–29); the stabilization group had a median of 25 months
(10–98) and in the worsened group the median was 19 (9–34).
Baseline FVC was significantly (p = 0.04.) lower in the good
responders and stabilized patients (median 75 (p25–75: 71–
92) and 83 (70–99)) compared to the poor responders (93 (84–
113)). A per-protocol analysis in the 44 patients who complet-
ed 12 cycles of CYC pulse therapy showed similar results.
Concomitant medication
A total of 51 patients (68%) received treatment with myco-
phenolate mofetil during follow-up. There were no baseline
differences between the users and non-users of mycopheno-
late mofetil. Also, there were no differences in FVC and
DLCO, nor in the change of FVC and DLCO, during
follow-up between patients receiving mycophenolate mofetil
and patients not receiving mycophenolate mofetil.
Treatment discontinuation
A total of 31 patients (41%) withdrew before the completion
of 12 monthly cycles of CYC. During the monthly cycles of
CYC pulses, four patients died (see section Survival). The
Table 1 Baseline characteristics
Total (n = 75) lcSSc (n = 33) dcSSc (n = 42) P value
Age in year, mean ± SD 58 ± 11 59 ± 10 57 ± 12 0.45
Male (%) 41 (55) 11 (33) 30 (71) 0.001
Months since first nRP* 20 (8–52) 26 (10–101) 19 (7–37) 0.07
Months SSc diagnosis-CYC* 3 (1–14) 4 (1–20) 3 (1–12) 0.49
SSc duration < 3 years (%) 50 (67) 18 (55) 32 (76) 0.048
Prior MTX use (%) 29 (39) 10 (30) 19 (45) 0.19
ATA (%) 36 (48) 12 (36) 24 (57) 0.074
ACA (%) 6 (8) 6 (18) 0 (0) 0.006
RNP (%) 3 (4) 2 (6) 1 (2) 0.58
ANA (%) 29 (39) 12 (36) 17 (41) 0.72
HRCT
% ground glass* 9 (1–21) 9 (1–24) 8 (0–19) 0.43
% fibrosis* 11 (6–22) 13 (6–22) 10 (4–24) 0.60
% disease extent* 23 (12–39) 24 (15–41) 23 (10–35) 0.29
GGO > fibrosis (%) 28 (37) 12 (36) 16 (38) 0.88
Limited ILD (%) 33 (44) 13 (39) 20 (48) 0.48
Pulmonary function
FVC, % of predicted* 86 (72–97) 83 (68–103) 87 (77–95) 0.58
DLCO, % of predicted* 42 (32–56) 42 (33–56) 43 (30–56) 0.87
Baseline DLCO < 60% (%) 59 (79) 26 (87) 33 (85) 0.55
All values are median (p25–75) unless stated otherwise. SD, standard deviation; dcSSc, diffuse cutaneous sys-
temic sclerosis; nRP, first non-Raynaud symptom; SSc duration < 3 years, SSc disease duration shorter than
3 years; CYC, cyclophosphamide; MTX, methotrexate; ANA, anti-nuclear antibodies (no ATA, ACA, or RNP);
ATA, anti-topoisomerase-I antibodies; ACA, anti-centromere antibodies; RNP, anti-ribonucleoprotein antibodies;
GGO > fibrosis, more GGO than fibrosis; FVC, forced vital capacity; DLCO, diffusing capacity of the lung for
carbon monoxide; HRCT, high-resolution computed tomography
Fig. 1 Pulmonary function test results at baseline and during follow-up at
12, 24, and 36 months
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Table 2 Pulmonary function test
during follow-up Baseline Follow-up Mean difference with
95% CI
P
value
% Δ baseline vs.
12 months
FVC 86 (72–97) 87 (77–99) 2.0 (−0.7–4.7) 0.15
FVC LOCF 85 (72–98) 1.2 (−1.5–3.8) 0.38
FVC PPA 87 (80–101) 1.6 (−1.5–4.6) 0.31
DLCO 42 (32–56) 45 (36–58) −0.5 (−2.8–1.7) 0.64
DLCO
LOCF
45 (33–57) −1.1 (−3.1–1.0) 0.30
DLCO PPA 47 (37–59) 0.1 (−2.5–2.8) 0.92
% Δ baseline vs.
24 months
FVC 86 (72–97) 91 (70–103) 2.0 (−2.3–6.2) 0.36
FVC LOCF 89 (70–100) 1.4 (−2.0–4.8) 0.41
FVC PPA 91 (70–106) 2.6 (−1.1–6.5) 0.17
DLCO 42 (32–56) 43 (35–57) 0.3 (−3.0–3.5) 0.88
DLCO
LOCF
43 (34–58) −0.9 (−3.5–1.8) 0.51
DLCO PPA 48 (37–58) 0.7 (−2.7–4.0) 0.68
% Δ baseline vs.
36 months
FVC 86 (72–97) 90 (72–103) 1.0 (−5.5–7.5) 0.77
FVC LOCF 89 (70–99) 1.3 (−2.7–5.3) 0.53
FVC PPA 90 (69–103) 2.2 (−1.9–6.3) 0.29
DLCO 42 (32–56) 43 (36–61) 1.6 (−2.5–5.7) 0.43
DLCO
LOCF
45 (36–61) −0.1 (−3.0–2.9) 0.97
DLCO PPA 48 (37–61) 0.6 (−2.8–4.0) 0.72
PFT values are median (p25-p75). FVC, forced vital capacity; DLCO, diffusing capacity of the lung for carbon
monoxide; LOCF, last observation carried forward; PPA, per-protocol analysis;CI, confidence interval; p value of
paired samples t test baseline versus follow-up (12, 24, or 36 months)
Table 3 Linear regression analysis
Δ 0–12 months Δ 0–24 months Δ 0–36 months
B SE (B) p value B SE (B) p value B SE (B) p value
FVC Constant − 0.3 4.4 0.96 − 1.1 5.6 0.85 − 2.7 6.5 0.68
GGO > fibrosis 0.2 2.6 0.92 0.9 3.3 0.78 1.8 3.8 0.64
Constant 1.5 3.7 0.68 3.0 4.7 0.52 − 2.2 5.4 0.68
Disease duration < 3 years − 1.0 2.6 0.69 − 2.0 3.3 0.56 1.9 3.9 0.63
Constant 1.6 4.2 0.70 3.2 5.3 0.55 3.5 6.1 0.56
Limited vs. extensive ILD − 0.9 2.6 0.72 − 1.8 3.2 0.58 − 2.1 3.7 0.58
Constant 1.3 4.3 0.77 0.6 5.6 0.92 − 2.3 6.5 0.73
Baseline DLCO < 60% − 0.4 3.6 0.91 0.6 4.7 0.90 2.9 5.5 0.60
DLCO Constant − 0.9 3.5 0.81 0.8 4.4 0.85 − 1.9 4.9 0.70
GGO > fibrosis − 0.7 2.1 0.75 − 1.6 2.6 0.54 0.5 2.9 0.85
Constant − 3.0 3.1 0.35 − 2.6 3.9 0.51 − 5.5 4.3 0.21
Disease duration < 3 years 0.8 2.2 0.73 0.7 2.8 0.81 3.3 3.1 0.28
Constant − 5.6 3.5 0.12 − 6.1 4.4 0.17 − 4.8 4.9 0.33
Limited vs. extensive ILD 2.4 2.2 0.28 2.9 2.8 0.30 2.5 3.1 0.42
Constant − 1.0 4.8 0.83 5.8 5.9 0.33 4.6 6.6 0.48
Baseline DLCO < 60% − 0.7 4.0 0.86 − 6.5 4.9 0.19 − 5.2 5.5 0.35
FVC, forced vital capacity;DLCO, diffusing capacity of the lung for carbonmonoxide;Δ, difference in% of predicted between two time points; B, beta;
SE, standard error; ILD, interstitial lung disease; GGO, ground glass opacity. All values are corrected for baseline values
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reasons for treatment discontinuation in the other 27 patients
were progression of ILD (13), pneumonia (3), excessive bur-
den on the patient (2), renal impairment (1), leucopenia/
th rombopen ia (1 ) , a l l e rg ic exan thema (1) , and
leukocytoclastic vasculitis (1). Additionally, there were four
patients who completed only six CYC pulses, due to a differ-
ent choice for the treatment strategy, for example to preserve
fertility. In one patient, the discontinuation reasonwas unclear.
There were no significant differences regarding treatment dis-
continuation between the probable effect modifiers: limited
and extensive ILD, more GGO than fibrosis, disease duration,
or baseline DLCO < 60%. Although not significant (p = 0.35),
in 11 out of 59 patients (18.6%) with a baseline DLCO < 60%,
the reason for treatment discontinuation was treatment ineffi-
cacy, compared to 0 out of 10 patients (0%) who had a base-
line DLCO > 60%.
Adverse events
Adverse events during treatment with CYC occurred in 17
cases (23%): pneumonia (7), anemia (4), leucopenia (2), and
hematuria, renal insufficiency, leukocytoclastic vasculitis, and
allergic exanthema (1).
No significant differences were seen in occurrence of ad-
verse events between limited and extensive ILD, more GGO
than fibrosis, disease duration, or baseline DLCO < 60%.
Survival
A total of 14 patients died during the CYC pulses (4) or during
the 3-year follow-up period (10).
Of the four patients who died during the CYC pulses, one
patient died after a complication of vascular surgery, and one
died of respiratory insufficiency following congestive heart
failure due to progression of ILD and pulmonary hypertension
(PH). Two patients died after a probable pneumonia compli-
cating their ILD. There were another 10 patients who died
during the 3-year follow-up period: progressive ILD/PH
(n = 4), progressive ILD (n = 2), metastasized colon carcino-
ma (n = 1), sepsis (n = 1), acute cardiac asthma (n = 1), and
SSc-related myocarditis (n = 1).
In Fig. 2, the Kaplan–Meier survival curve is displayed,
showing that most patients died in the first year after the start
of CYC pulses. The overall 3-year survival rate in the 75
patients who started CYC pulses was 81%. Survival in the
lcSSc patients was 76% compared to 86% in dcSSc patients;
this was a non-significant difference (log-rank 0.30). The ef-
fect modifiers (more GGO than fibrosis, disease duration, lim-
ited ILD, or baseline DLCO < 60%) showed no significant
difference in survival (not shown).
Discussion
The present study shows that high-dose treatment with CYC
leads to a sustained stabilization of pulmonary function in
patients with ILD associated with SSc. We found that both
vital capacity and carbon monoxide capacity of the lungs
remained stable for 3 years after treatment with CYC. The
treatment effect seemed to be independent of the inflammato-
ry phase of ILD; proxies for disease activity did not signifi-
cantly alter the treatment effect.
According to the EULAR treatment recommendations,
CYC is the first choice treatment for SSc-ILD [9]. The effect
of CYC on pulmonary function as demonstrated in other stud-
ies is confirmed by the results of the current study [13–16,
19–21, 31]. In this study, we also were able to show long-
term stabilization of pulmonary function during 3 years of
follow-up, as well as an overall 3-year survival rate of 81%.
Besides, this study has identified a subgroup of good re-
sponders. On the opposite, treatment with CYC also has its
downsides, with adverse events occurring in almost one in
four patients.
As stated in the BIntroduction,^ we hypothesized that CYC
might be more effective if SSc-ILD still has a large inflamma-
tory component while fibrosis is less present. We have collect-
ed four proxies of inflammatory activity and inflammation to
approach this as closely as possible (the proportion of ground
glass, SSc disease duration, extent of ILD according to Goh’s
criteria, and baseline DLCO < 60%).
Contrary to our hypothesis, none of these proxies showed
could predict a good treatment response in our cohort of SSc-
ILD patients. This might have several explanations. First, the
treatment effect of CYCmight be independent of the extent of
ILD. Second, the proxies we chose might have reflected the
early inflammatory phase inadequately. Third, inflammation
might not be the driving factor for the treatment effect of
CYC. Thus, there is a lack of proper proxies for treatment
effect in SSc-ILD. The underlying issue is the lack of a gold
standard for inflammation in interstitial lung disease. In order
to gain further insight, future research should focus on the
pathophysiology of SSc-ILD to identify relevant markers that
show good respond to CYC treatment.
Predictors of a good response on CYC therapy are pivotal. In
our study, 19% had a predefined good response, 55% of the
patients had stabilized pulmonary function test results, and 27%
worsened during follow-up. Although we could not find a robust
treatment effect of our proxies, there was some evidence that
patients with a short disease duration respond better. Baseline
FVC in the good responders was remarkably significantly lower
than that in the poor responder group, but this might be a result of
less loss of FVC in the poor responder group: Bless loss, less to
regain.^ The failure of our proxies to identify relevant subgroups
of patients that might respond better to cyclophosphamide treat-
ment underlines the need for better treatment surrogates in future
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trials, especially in light of the rate of serious adverse events seen
in the present study.
The use of MMF in SSc-ILD has increased over the last
decade. In our center, MMF is often described after CYC infu-
sions. We found no differences in MMF users and non-users in
both baseline and follow-up results. Therefore, we could not
prove an additional effect of MMF following CYC treatment
as was found in the study performed by Tashkin et al. [31].
There are some limitations to this study. The most impor-
tant limitation probably is our choice of the four surrogate
markers for an Bearly^ inflammatory phase in SSc-ILD.
There is no gold standard available to measure the amount
of inflammation in ILD.We have tried to choose several com-
ponents which might reflect the early, inflammatory, revers-
ible phase of SSc-ILD. Ground glass opacities seen on HRCT
indicate the presence of alveolitis, which is still reversible.
Secondly, 75 out of 91 patients who started with CYC pulses
because of SSc-ILD were analyzed in this study. The 16 pa-
tients all dropped out due to missing baseline HRCT (n = 15)
or PFT (n = 1), not because of specific disease-related causes.
Therefore, the probability of bias is small.
In conclusion, overall pulmonary function in SSc-related
ILD measured by FVC and DLCO shows stabilization after
intravenous CYC pulses during a 3-year follow-up period.
One fifth of the patients improved, more than half stabilized,
and a quarter worsened. A significant part of the patients died
during the follow-up period. The different inflammatory ac-
tivity proxies, proportion of ground glass, SSc disease dura-
tion, extent of ILD, and baseline DLCO do not influence the
effect of CYC on pulmonary function. Therefore, based on the
results of both previous RCTs and the results of this study,
CYC appears to be an appropriate therapy for a large propor-
tion of patients with SSc-ILD; subgroups of patients with
good or no response could not be identified. Future studies
should focus on identifying relevant markers of inflammation
to better select those patients with SSc-ILD that will have the
best response to this intensive treatment.
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